Inhibition for Immunosuppression

Publisher Website
Google Scholar
Abstract
To the Editor: Polmar et al.1 established a cause- and-effect relation between adenosine deaminase deficiency and combined immunodeficiency by restoring immunocompetency to a seven-month-old infant with adenosine deaminase deficiency associated with severe combined immunodeficiency by transfusion of human red cells containing normal adenosine deaminase activity. Their observation suggested to us that specific inhibition of such activity might be a useful technic for immunosuppressive therapy.In 1967 Schaeffer and Schwender examined hydrophobic and hydroxylic binding sites of adenosine deaminase and synthesized a number of substituted substrate analogues,2 one of them being erythro-9(2-hydroxy-3-nonyl)-adenine hydrochloride (EHNA).3 Agarwal et al. recognized that EHNA . . .